Translational psychiatry-light at the end of the tunnel

Annals of the New York Academy of Sciences

Volumn 1344, Issue 1, 2015, Pages 1-11

  Jones, Kenneth A ^a   Menniti, Frank S ^b   Sivarao, Digavalli V ^c  

^a Cyanaptic LLC   (United States)

^b Mnemosyne Pharmaceuticals Inc   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biomarker; Electroencephalography; Glutamate; Ketamine; Psychiatry; Translational

Indexed keywords

BIOLOGICAL MARKER; GLUTAMIC ACID;

ALPHA RHYTHM; ARTICLE; BRAIN FUNCTION; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; ENDOPHENOTYPE; HIGH FREQUENCY OSCILLATION; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; PROTEOMICS; PSYCHIATRY; RECEPTOR OCCUPANCY; SYNAPTIC TRANSMISSION; THALAMUS RETICULAR NUCLEUS; TRANSCRIPTOMICS; TRANSLATIONAL PSYCHIATRY; BLOOD; DEPRESSION; DRUG DESIGN; GENE EXPRESSION PROFILING; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; SCHIZOPHRENIA; TRANSLATIONAL RESEARCH; TRENDS;

BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSION; DRUG DESIGN; GENE EXPRESSION PROFILING; HUMANS; PROTEOMICS; PSYCHIATRY; SCHIZOPHRENIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84928281821     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12725     Document Type: Article

References (100)

1. Hyman, S.E. 2012. Revolution stalled. Sci. Transl. Med. 4: 155cm11.
2. Morgan, P. et al. 2012. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17: 419-424.
3. Berk, M. 2012. Pathways to new drug discovery in neuropsychiatry. BMC Med. 10: 151.
4. Brady, L.S. & T.R. Insel . 2012. Translating discoveries into medicine: psychiatric drug development in 2011. Neuropsychopharmacology 37: 281-283.
5. Singh, I. & N. Rose . 2009. Biomarkers in psychiatry. Nature 460: 202-207.
6. Insel, T.R. & N. Gogtay . 2014. National Institute of Mental Health clinical trials: new opportunities, new expectations. JAMA Psychiatry 71: 745-746.
7. Grayton, H.M. et al. 2012. Copy number variations in neurodevelopmental disorders. Prog. Neurobiol. 99: 81-91.
8. Markou, A. et al. 2009. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34: 74-89.
9. Corvin, A. & D.W. Morris . 2014. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol. Psychiatry 75: 276-283.
10. Gatt, J.M. et al. 2015. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J. Psychiatr. Res. 60: 1-13.
11. Harrison, P.J. 2015. Recent genetic findings in schizophrenia and their therapeutic relevance. J. Psychopharmacol. 29: 85-96.
12. Donaldson, Z.R. & R. Hen . 2015. From psychiatric disorders to animal models: a bidirectional and dimensional approach. Biol. Psychiatry 77: 15-21.
13. Flood, D.G., G.J. Marek & M. Williams . 2011. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem. Pharmacol. 81: 1422-1434.
14. Brady, L. 2014. Biomarker development and validation: establishing standards of evidence for their context of use in clinical trials. NAMHC Concept Clearance. National Institute of Mental Health. Accessed February 17, 2015. http://www.nimh.nih.gov/funding/grant-writing-and-application-process/concept-clearances/2014/biomarker-development-and-validation-establishing-standards-of-evidence-for-their-context-of-use-in-clinical-trials.shtml
15. Borsook, D. & L. Becerra . 2010. Using NMR approaches to drive the search for new CNS therapeutics. Curr. Opin. Investig. Drugs 11: 771-778.
16. Borsook, D., L. Becerra & R. Hargreaves . 2006. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 5: 411-424.
17. Kaur, M. et al. 2013. Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 46: 161-169.
18. Perez, V.B. et al. 2014. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol. Psychiatry 75: 459-469.
19. Babiloni, C. et al. 2009. Fundamentals of electroencefalography, magnetoencefalography, and functional magnetic resonance imaging. Int. Rev. Neurobiol. 86: 67-80.
20. Pajer, K. et al. 2012. Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression. Transl. Psychiatry 2: e101.
21. Redei, E.E. et al. 2014. Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy. Transl. Psychiatry 4: e442.
22. Redei, E.E. & N.S. Mehta . 2015. Blood transcriptomic markers for major depression: from animal models to clinical settings. Ann. N.Y. Acad. Sci. 1344: 37-49.
23. Luck, S.J. et al. 2011. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol. Psychiatry 70: 28-34.
24. Bewernitz, M. & H. Derendorf . 2012. Electroencepha-logram-based pharmacodynamic measures: a review. Int. J. Clin. Pharmacol. Ther. 50: 162-184.
25. Leiser, S.C. et al. 2011. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem. Pharmacol. 81: 1408-1421.
26. Mandema, J.W. & M. Danhof . 1992. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin. Pharmacokinet. 23: 191-215.
27. Bronzino, J.D. 2000. "Principles of electroencephalography." In The Biomedical Engineering Handbook. J.D. Bronzino, Ed.: 201-212. Boca Raton: CRC Publishers LLC.
28. Thakor, N.V. & S. Tong . 2004. Advances in quantitative electroencephalogram analysis methods. Annu. Rev. Biomed. Eng. 6: 453-495.
29. Buzsaki, G. & A. Draguhn . 2004. Neuronal oscillations in cortical networks. Science 304: 1926-1929.
30. Chrobak, J.J. & G. Buzsaki . 1998. Gamma oscillations in the entorhinal cortex of the freely behaving rat. J. Neurosci. 18: 388-398.
31. Lakatos, P. et al. 2005. An oscillatory hierarchy controlling neuronal excitability and stimulus processing in the auditory cortex. J. Neurophysiol. 94: 1904-1911.
32. Llinas, R.R. 1988. The intrinsic electrophysiological properties of mammalian neurons: insights into central nervous system function. Science 242: 1654-1664.
33. Llinas, R.R. & M. Steriade . 2006. Bursting of thalamic neurons and states of vigilance. J. Neurophysiol. 95: 3297-3308.
34. Brett, B., G. Krishnan & D.S. Barth . 1996. The effects of subcortical lesions on evoked potentials and spontaneous high frequency (gamma-band) oscillating potentials in rat auditory cortex. Brain Res. 721: 155-166.
35. Gray, C.M. & D.A. McCormick . 1996. Chattering cells: superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex. Science 274: 109-113.
36. Barth, D.S. & K.D. MacDonald . 1996. Thalamic modulation of high-frequency oscillating potentials in auditory cortex. Nature 383: 78-81.
37. Steriade, M. et al. 1996. Synchronization of fast (30-40 Hz) spontaneous oscillations in intrathalamic and thalamocortical networks. J. Neurosci. 16: 2788-2808.
38. Sanacora, G. et al. 2014. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 19: 978-985.
39. Buhrer, M. et al. 1990. Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. Clin. Pharmacol. Ther. 48: 555-567.
40. Danhof, M. et al. 2008. Mechanism-based pharmaco-kinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29: 186-191.
41. Mandema, J.W., E. Tukker & M. Danhof . 1992. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J. Pharmacol. Exp. Ther. 260: 36-44.
42. Sebban, C. et al. 2002. Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. Br. J. Pharmacol. 135: 65-78.
43. Fiset, P. et al. 1995. Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam. Clin. Pharmacol. Ther. 58: 567-582.
44. Homayoun, H. & B. Moghaddam . 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27: 11496-11500.
45. Pinault, D. 2008. N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol. Psychiatry 63: 730-735.
46. Carlen, M. et al. 2012. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol. Psychiatry 17: 537-548.
47. Mandema, J.W. et al. 1992. Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures. J. Pharmacol. Exp. Ther. 261: 88-95.
48. Cao, Z. et al. 2000. Postnatal development of NR1, NR2A and NR2B immunoreactivity in the visual cortex of the rat. Brain Res. 859: 26-37.
49. Conti, F. et al. 1999. Neuronal and glial localization of NR1 and NR2A/B subunits of the NMDA receptor in the human cerebral cortex. Cereb. Cortex 9: 110-120.
50. Mower, G.D. & L. Chen . 2003. Laminar distribution of NMDA receptor subunit (NR1, NR2A, NR2B) expression during the critical period in cat visual cortex. Brain Res. Mol. Brain Res. 119: 19-27.
51. Huang, M. et al. 2014. The novel alpha7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl). 231: 4541-4551.
52. Rezvani, A.H. et al. 2009. Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 33: 269-275.
53. Grimwood, S. & P.R. Hartig . 2009. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol. Ther. 122: 281-301.
54. Hume, S.P. et al. 2007. Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates. J. Pharmacol. Exp. Ther. 322: 661-667.
55. Niswender, C.M. & P.J. Conn . 2010. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50: 295-322.
56. Traynelis, S.F. et al. 2010. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62: 405-496.
57. Citri, A. & R.C. Malenka . 2008. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33: 18-41.
58. Cull-Candy, S.G., S. Brickley & M. Farrant . 2001. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11: 327-335.
59. Malenka, R.C. & R.A. Nicoll . 1993. NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends Neurosci. 16: 521-527.
60. Domino, E.F. & E.D. Luby . 2012. Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophr. Bull. 38: 914-919.
61. Javitt, D.C. et al. 2012. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr. Bull. 38: 958-966.
62. Krystal, J.H. et al. 2003. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169: 215-233.
63. Javitt, D.C. et al. 2011. Translating glutamate: from pathophysiology to treatment. Sci. Transl. Med. 3: 102mr2.
64. Olney, J.W., J.W. Newcomer & N.B. Farber . 1999. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33: 523-533.
65. Javitt, D.C. & S.R. Zukin . 1991. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148: 1301-1308.
66. Hall, J. et al. 2015. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol. Psychiatry 77: 52-58.
67. Moghaddam, B. & J.H. Krystal . 2012. Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr. Bull. 38: 942-949.
68. Berman, R.M. et al. 2000. Antidepressant effects of keta-mine in depressed patients. Biol. Psychiatry 47: 351-354.
69. Zarate, C.A. et al. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63: 856-864.
70. Aan Het Rot, M. et al. 2012. Ketamine for depression: where do we go from here? Biol. Psychiatry 72: 537-547.
71. Murrough, J.W. & D.S. Charney . 2010. Cracking the moody brain: lifting the mood with ketamine. Nat. Med. 16: 1384-1385.
72. Niciu, M.J. et al. 2014. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Rev. Pharmacol. Toxicol. 54: 119-139.
73. Duman, R.S. et al. 2012. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35-41.
74. Dwyer, J.M. & R.S. Duman . 2013. Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol. Psychiatry 73: 1189-1198.
75. Kavalali, E.T. & L.M. Monteggia . 2012. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am. J. Psychiatry 169: 1150-1156.
76. Li, N. et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
77. Li, N. et al. 2011. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69: 754-761.
78. Maeng, S. et al. 2008. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63: 349-352.
79. Lener, M.S. & D.V. Iosifescu . 2015. In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature. Ann. N.Y. Acad. Sci. 1344: 50-65.
80. Javitt, D.C. 2015. Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. Ann. N.Y. Acad. Sci. 1344: 92-104.
81. Abdallah, C.G., L.A. Averill & J.H. Krystal . 2015. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann. N.Y. Acad. Sci. 1344: 66-77.
82. Featherstone, R.E. et al. 2015. EEG biomarkers of target engagement, therapeutic effect, and disease process. Ann. N.Y. Acad. Sci. 1344: 12-26.
83. Sivarao, D.V. 2015. The 40-Hz auditory steady-state response: a selective biomarker for cortical NMDA function. Ann. N.Y. Acad. Sci. 1344: 27-36.
84. Leuchter, A.F. et al. 2015. Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments. Ann. N.Y. Acad. Sci. 1344: 78-91.
85. MacDonald, J.F., Z. Miljkovic & P. Pennefather . 1987. Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J. Neurophysiol. 58: 251-266.
86. Jackson, M.E., H. Homayoun & B. Moghaddam . 2004. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. USA. 101: 8467-8472.
87. Kocsis, B. 2012. Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol. Psychiatry 71: 987-995.
88. Cornwell, B.R. et al. 2012. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol. Psychiatry 72: 555-561.
89. Zarate, C.A., Jr. et al. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71: 939-946.
90. Rodriguez, C.I. et al. 2013. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38: 2475-2483.
91. Feder, A. et al. 2014. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71: 681-688.
92. Paoletti, P., C. Bellone & Q. Zhou . 2013. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14: 383-400.
93. Fischer, G. et al. 1997. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. 283: 1285-1292.
94. Menniti, F.S. et al. 1998. CP-101606: an NR2B-selective NMDA receptor antagonist. CNS Drug Rev. 4: 307-322.
95. Bullock, M.R. et al. 1999. An open-label study of CP-101606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. N.Y. Acad. Sci. 890: 51-58.
96. Merchant, R.E. et al. 1999. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101606 in patients with a mild or moderate traumatic brain injury. Ann. N.Y. Acad. Sci. 890: 42-50.
97. Nutt, J.G. et al. 2008. Effects of a NR2B selective NMDA glutamate antagonist, CP-101606 on dyskinesia and Parkinsonism. Mov. Disord. 23: 1860-1866.
98. Preskorn, S.H. et al. 2008. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101606 in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28: 631-637.
99. Sivarao, D.V. et al. 2014. NR2B antagonist CP-101606 abolishes pitch-mediated deviance detection in awake rats. Front. Psychiatry 5: 96.
100. Matta, J.A. et al. 2013. Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity. Nat. Neurosci. 16: 1032-1041.